ALMS

ALMS
Name	ALMS
Specialty	Endocrinology, Genetics, Ophthalmology
Symptoms	Multisystemic progressive features
Onset	Childhood to adolescence
Causes	Mutations in ALMS1 gene
Frequency	Rare

ALMS

ALMS is a rare, multisystemic, autosomal recessive syndrome characterized by progressive retinal dystrophy, early-onset obesity, sensorineural hearing loss, insulin-resistant type 2 diabetes mellitus, and progressive cardiomyopathy. First delineated through clinical series that involved specialist centers such as Massachusetts General Hospital and reports from consortia including the World Without Obesity research groups, the disorder is linked to pathogenic variants in the ALMS1 locus discovered in molecular studies at institutions like Harvard Medical School and Stanford University School of Medicine. Management commonly requires coordinated care across clinics such as Mayo Clinic, Johns Hopkins Hospital, and pediatric metabolic centers.

Overview

ALMS is caused by biallelic mutations in the ALMS1 gene located on chromosome 2, identified through linkage analysis and sequencing efforts led by teams at University College London and the National Institutes of Health. The phenotype comprises early childhood onset of retinal degeneration analogous to features described in cohorts from Great Ormond Street Hospital and parallels with other ciliopathies catalogued in databases curated by European Molecular Biology Laboratory and ClinVar. Clinical descriptions have been published in journals associated with American Academy of Pediatrics and European Society of Human Genetics guidelines.

Causes and Pathophysiology

Pathogenic variants in ALMS1 disrupt a protein localized to centrosomes and basal bodies of primary cilia, a mechanism elucidated in cellular models at University of Cambridge and Max Planck Institute for Molecular Genetics. The resulting ciliary dysfunction affects tissues with high sensory or metabolic demands, a concept reinforced by comparative studies involving Bardet–Biedl syndrome cohorts from University of Oxford and Johns Hopkins University. Fibroblast and induced pluripotent stem cell lines studied at Cold Spring Harbor Laboratory and Karolinska Institutet show defective intracellular trafficking and abnormal signaling pathways shared with research on Nephronophthisis and Joubert syndrome. Cardiac studies from Cleveland Clinic and Mount Sinai Hospital indicate myocardial fibrosis, while hepatic investigations from Addenbrooke's Hospital report steatohepatitis and variable progression to portal fibrosis.

Clinical Presentation and Diagnosis

Children typically present with nystagmus and visual impairment noted by ophthalmology services at centers such as Bascom Palmer Eye Institute and Moorfields Eye Hospital, progressing to legal blindness similar to courses reported for Leber congenital amaurosis. Early-onset obesity prompts evaluation in pediatric endocrinology clinics like those at Children's Hospital of Philadelphia and Boston Children's Hospital, where insulin resistance and dyslipidemia akin to metabolic syndrome are documented. Sensorineural hearing loss is managed through audiology programs at St. Jude Children's Research Hospital and Royal National Throat, Nose and Ear Hospital. Cardiac presentation ranges from dilated cardiomyopathy described in case series from European Society of Cardiology registries to arrhythmias reported by electrophysiology teams at University of Pennsylvania Health System. Diagnosis integrates molecular genetic testing provided by laboratories at GeneDx and Ambry Genetics along with imaging modalities used at John Radcliffe Hospital and electroretinography protocols standardized by groups like the International Society for Clinical Electrophysiology of Vision.

Management and Treatment

There is no disease-modifying therapy approved by regulatory agencies such as the US Food and Drug Administration or the European Medicines Agency; care is multidisciplinary, drawing on specialty clinics at Cleveland Clinic and coordinated networks exemplified by European Reference Networks. Ophthalmologic support includes low-vision services at Smith-Kettlewell Eye Research Institute and assistive technologies developed in collaboration with National Federation of the Blind. Metabolic management employs interventions studied in trials at Joslin Diabetes Center and dietetic programs at University of California, San Francisco to address insulin resistance and dyslipidemia; some patients receive pharmacotherapy typical for type 2 diabetes mellitus including agents evaluated in multicenter trials by American Diabetes Association investigators. Cardiac care follows heart failure guidelines from American College of Cardiology and may involve medical therapy, device implantation, or transplantation as coordinated by centers like Cleveland Clinic Foundation. Hearing loss is treated with hearing aids or cochlear implantation per protocols practiced at House Ear Institute.

Prognosis and Epidemiology

ALMS is rare with estimated prevalence varying by population; founder mutations have been reported in consanguineous communities and in regions studied by population genetics groups at University of Toronto and University of Auckland. Longitudinal cohort data collected by registries affiliated with Orphanet and specialty centers report variable life expectancy influenced by severity of cardiomyopathy and metabolic complications, paralleling prognostic patterns seen in other monogenic syndromes tracked by National Organization for Rare Disorders. Morbidity often stems from progressive vision and hearing loss, hepatic fibrosis noted in hepatology series from Royal Free Hospital, and complications of diabetes catalogued by National Health Service audit programs.

Research and Emerging Therapies

Preclinical studies at Massachusetts Institute of Technology and University of California, San Diego employ gene-replacement strategies, antisense oligonucleotides, and ciliary-targeted small molecules informed by work on gene therapy for retinal dystrophies at University of Florida and translational pipelines at Spark Therapeutics. Natural history initiatives coordinated with patient advocacy organizations such as Alström Syndrome International and data-sharing consortia modeled on Global Rare Disease Registry efforts aim to support clinical trials at academic sites including Yale School of Medicine and Imperial College London. Ongoing research into modifier genes leverages genome-wide association methods developed at Wellcome Sanger Institute and large-scale sequencing collaborations with Broad Institute.

Category:Rare genetic disorders